Experienced in Anaphylaxis

Hironori Sagara

Tokyo, JP 
Experienced in Anaphylaxis
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Hironori Sagara practices in Tokyo, Japan. Sagara is rated as an Experienced expert by MediFind in the treatment of Anaphylaxis. Their top areas of expertise are Asthma, Eosinophilic Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Allergic Rhinitis.

Their clinical research consists of co-authoring 140 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 6 articles in the study of Anaphylaxis.

Locations

Tokyo, Japan
Other Locations
Hatanodai, Japan
Showa, Japan
Koshigaya, Japan
Tochigi, Japan
Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
View 1 Less Clinical Trial

140 Total Publications

TO INCREASE COVID-19 VACCINATION RATE OF SEVERELY ALLERGIC PATIENTS UTILIZE REGIONAL COLLABORATION
TO INCREASE COVID-19 VACCINATION RATE OF SEVERELY ALLERGIC PATIENTS UTILIZE REGIONAL COLLABORATION
Journal: Arerugi = [Allergy]
Published: August 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Sagara's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile